Core Viewpoint - Mirxes-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the FDA in the US [1] - GASTROClear has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - Guoyuan International believes that the company has significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as one of the global leaders in this sector [1] - Everbright Securities International previously noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share (66.3%) in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]

公开资料显示，Mirxes觅瑞是一家以新加坡为总部的RNA生物科技公司，致力于开发及商业化针对癌症 及其他疾病早期筛查的精准、无创、可负担的血液miRNA检测。公司旗舰产品GASTROClear™/觅小卫 ™是一款基于血液miRNA的胃癌筛查分子检测试剂盒，已在包括新加坡及欧盟的多国获批，并取得美 国FDA突破性医疗器械认证。觅小卫™在中国已经完成了一项样本规模为9,472人的前瞻性临床试验， 目前正在注册申请中。 国元国际认为，公司在基于miRNA的癌症早期检测领域具有显著的技术、产品和市场优势，是该领域 的全球领导者之一。光大证券国际此前指出，全球癌症筛查市场空间广阔，行业进入壁垒高。 GASTROClear™是全球市场上唯一一款获批准进行胃癌筛查的分子诊断IVD产品，按2023年收益计，在 东南亚基于miRNA的液体活检胃癌筛查市场上拥有最大的市场份额（市场份额为66.3%）。 智通财经APP获悉，MIRXES-B(02629)涨近9%，高见40.66港元创上市新高，较招股价23.3港元已涨超 七成。截至发稿，涨8.96%，报40.62港元，成交额1666.18万港元。 ...